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Background
Synchronized direct current cardioversion (CV) is a common treatment for atrial fibrillation (AF) if
primary treatment with anti-arrhythmic drugs fails. However, direct current CV, without
pretreatment precautions, is associated with an increased risk of embolic stroke, presumably due
to dislodgement of intracardiac thrombi. In order to prevent such complications, patients are
typically treated with systemic anticoagulants for at least 3 weeks prior to cardioversion. (1)
Warfarin has historically been the standard for anticoagulant treatment in AF. Warfarin reduces
the risk of embolic stroke by 66% in AF patients. In addition, warfarin is relatively inexpensive and
unaﬀected by renal function, which makes it a popular anticoagulant drug. (2)
Direct oral anticoagulants (DOACs such as apixaban, dabigatran, rivaroxaban and edoxaban) are
becoming more prevalent in use. DOACs directly inhibit clotting factors instead of targeting
Vitamin K as warfarin does. Apixaban, rivaroxaban and edoxaban are reversible inhibitors of
Factor Xa. Dabigatran is a reversible inhibitor of thrombin.
DOACs are being increasingly used in place of warfarin to prevent embolic stroke in AF but there is
limited data on their eﬃcacy and safety in the setting of elective CV for AF, particularly compared
to warfarin.

Hypothesis
Our hypothesis was that DOACs are not inferior to warfarin in preventing adverse events and
recurrent AF following elective CV. To test this, we analyzed 30-day outcomes from an ongoing
three-year outpatient CV registry.
We sought to determine the following objectives:
• The rate of adverse events within 30 days following all cardioversions on patients treated with
warfarin vs. DOACs.
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Table 3: List of patients that experienced an adverse event within 30 days
of their elective cardioversion. Arbitrary letters were used to de-identify the
patients' data. Of significance, 4/5 patients with an adverse event were not
on Aspirin (P-value = 0.1875 using a binomial distribution). In addition,
3/5 of the patients with adverse events suﬀered from embolic events while
2/5 suﬀered from hemorrhagic events.

Table 1: Clinical Characteristics
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Table 2: Table showing outcomes
surveyed concerning the rate of adverse
events (defined as Stroke, Intracranial
Hemorrhage, and ISTH Major Bleeding)
within 30 days following CV and the
rate of recurrence of atrial fibrillation
within 30 days following CV.
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Figure 1: Graph showing the insignificant diﬀerence in the recurrence rate of
A-fib for patients on Warfarin vs. DOACs.

• The rate of AF recurrence within 30 days post-cardioversion in patients on warfarin vs. DOACs.

Methods
Patient charts from the ongoing registry (May 2013 – May 2016) of elective synchronized direct
current CV at Parkview Heart Institute were analyzed. The elective distinction was made in order to
exclude CVs done in emergency situations or in situations where the patient could be at risk for
other comorbidities; thus, by only including outpatients, several confounding variables were
avoided. Of significance, each CV was treated as a separate data point even if a given patient had
multiple treatments. Multiple co-variants were examined and shown in Table 1.

Results
Overall, 960 CVs were surveyed, but 441 were excluded from the study using the criteria listed above (Note that 13/226
pre-procedural TEEs showed intracardiac thrombus and thus their data were excluded from the study because no CV was
performed). Two main outcomes were surveyed, with regards to the adverse event rate for patients within 30 days following
CV, which are shown in Table 2. For the purpose of this study, adverse events were defined to include both bleeding and
embolic events regardless of their diﬀerence in pathology (Table 3).
Adverse events and recurrence of AF after 30 days were not considered in this study in order to ensure that any complications
observed were likely due to the CV itself and not any other disease states, accidents or complicating conditions.
A two-tailed Fischer Exact Test was not able to show a relationship of dependence between treatment type (warfarin vs.
DOACs) and frequency of adverse events (P-value = 0.6103). Specifically, 2/137 patients on warfarin experienced adverse
events within 30 days, whereas 3/382 patients on DOACs experienced adverse events within 30 days. Due to the low
occurrence rates seen in this study, the statistical power of this test (found by simulation, using 10,000 data sets) was found
to be only ~0.087.
Likewise, a two sided 2 sample z test for proportions was not able to show a significant diﬀerence between the rate of
recurrence of atrial fibrillation for warfarin vs. DOACs within 30 days following cardioversion (P-value = 0.5419). Specifically,
41/130 (31.5%) of patients on warfarin experienced a recurrence of AF within 30 days, whereas 116/336 (34.5%) of patients
on DOACs experienced a recurrence within 30 days. The statistical power of this test was found to be 0.095.
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Cardioversions at Parkview Hospital were found to be safe. The rate of adverse events within 30
days following cardioversion was found to be only 5/519 (0.963%). However, the rate of atrial
fibrillation recurrence within 30 days was found to be 157/466 (33.7%).
No significant relationship of dependence was seen between treatment type (warfarin vs. DOACs)
and adverse event rate within 30 days. Due to the very low occurrence rate of adverse events, the
statistical power of this analysis was quite low. Likewise, no significant relationship of
dependence was seen between treatment type and recurrence of AF within 30 days.

Discussion
Since the emergence of DOACS in 2010, several large randomized controlled trials have
demonstrated their eﬃcacy and safety in preventing embolic stroke in AF. Subset analyses of
patients undergoing CV during these studies have not shown a significant diﬀerence in outcomes
between patients randomized to DOACs versus warfarin. (3) A recent study demonstrated
significantly less adverse events using treatment with apixaban compared to treatment with
heparin/vitamin K antagonists in AF patients undergoing scheduled cardioversion. (4) None of
these studies examined the incidence of AF recurrence following CV in either treatment type.
Our study adds important real-world data applicable to this common clinical setting and provides
additional support for the continued use of DOACs in place of warfarin for anticoagulation prior to
CV. It is becoming increasingly evident that providers can be comfortable using DOACs prior to CV
without the fear of lessened eﬃcacy or safety.
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